Abstract
Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS. Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target lesion, left ventricular ejection fraction ≤25% and at increased bleeding risk are excluded. All patients are treated with dual antiplatelet therapy for two months. The primary endpoint is in-stent late luminal loss (LL) at 6-month follow-up angiography. Secondary endpoints are the incidence of major adverse cardiovascular events (MACE) and stent thrombosis over 12 months after randomisation. Patients' enrolment is open in all centres. Conclusions: This study will address the important question of safety and efficacy of a novel, inert and highly compatible passive coating on a thin-strut BMS with a great potential to be superior to a non-coated widely used BMS.
| Original language | English |
|---|---|
| Pages (from-to) | 976-980 |
| Number of pages | 5 |
| Journal | EuroIntervention |
| Volume | 5 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Apr 2010 |
Fingerprint
Keywords
- Cobalt chromium stent
- Coronary artery disease
- Restenosis
- Stent
- Study design
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Medicine(all)
Cite this
A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions : Study design and protocol. / Kastrati, Adnan; Balducelli, Marco; Di Sciascio, Germano; Moccetti, Tiziano; Bortone, Alessandro S.; Colombo, Antonio; Waltenberger, Johannes; Hehrlein, Christoph.
In: EuroIntervention, Vol. 5, No. 8, 04.2010, p. 976-980.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions
T2 - Study design and protocol
AU - Kastrati, Adnan
AU - Balducelli, Marco
AU - Di Sciascio, Germano
AU - Moccetti, Tiziano
AU - Bortone, Alessandro S.
AU - Colombo, Antonio
AU - Waltenberger, Johannes
AU - Hehrlein, Christoph
PY - 2010/4
Y1 - 2010/4
N2 - Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS. Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target lesion, left ventricular ejection fraction ≤25% and at increased bleeding risk are excluded. All patients are treated with dual antiplatelet therapy for two months. The primary endpoint is in-stent late luminal loss (LL) at 6-month follow-up angiography. Secondary endpoints are the incidence of major adverse cardiovascular events (MACE) and stent thrombosis over 12 months after randomisation. Patients' enrolment is open in all centres. Conclusions: This study will address the important question of safety and efficacy of a novel, inert and highly compatible passive coating on a thin-strut BMS with a great potential to be superior to a non-coated widely used BMS.
AB - Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS. Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target lesion, left ventricular ejection fraction ≤25% and at increased bleeding risk are excluded. All patients are treated with dual antiplatelet therapy for two months. The primary endpoint is in-stent late luminal loss (LL) at 6-month follow-up angiography. Secondary endpoints are the incidence of major adverse cardiovascular events (MACE) and stent thrombosis over 12 months after randomisation. Patients' enrolment is open in all centres. Conclusions: This study will address the important question of safety and efficacy of a novel, inert and highly compatible passive coating on a thin-strut BMS with a great potential to be superior to a non-coated widely used BMS.
KW - Cobalt chromium stent
KW - Coronary artery disease
KW - Restenosis
KW - Stent
KW - Study design
UR - http://www.scopus.com/inward/record.url?scp=77957025430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957025430&partnerID=8YFLogxK
U2 - 10.4244/EIJV5I8A163
DO - 10.4244/EIJV5I8A163
M3 - Article
VL - 5
SP - 976
EP - 980
JO - EuroIntervention
JF - EuroIntervention
SN - 1774-024X
IS - 8
ER -